Technology
„Ready to Use“ R&D and GMP Cell Banks for Vaccine Manufacturing
Nuvonis cell banks are state-of-the-art, as they were generated under serum-free and animal component-free conditions and grow in a medium that is commercially available. Currently, fully tested Vero cell banks (both GMP and R&D) and novel avian/quail cell banks (both GMP and R&D) are available.
Process Development for Vaccine Manufacturing (Upstream/Downstream)
The Nuvonis team is highly experienced in the development and optimization of up- and downstream vaccine production processes . We are offering a proprietary and efficient virus purification process for the generation of high-purity vaccine bulk drug substance, meeting regulatory requirements in terms of host cell DNA and host cell protein limits.
Influenza Virus Generation by Reverse Genetics
The Nuvonis team is highly experienced in the generation of influenza viruses by reverse genetics. Nuvonis uses a proprietary method to generate vaccine strains within days in serum-free Vero cells. The method is extremely fast, efficient, and reliable.
FAQ
Providing GMP Master and Working Cell Banks for vaccine development and production to our clients. Fully characterized MCB and WCB banks including tumorigenicity testing at the end of production level (EPCB).
Papers
The Nuvonis team is highly experienced in the development and optimization of up- and downstream vaccine production processes.
We are offering a proprietary and efficient virus purification process for the generation of high-purity vaccine bulk drug substance meeting regulatory requirements in terms of host cell DNA and protein limits.